论文部分内容阅读
目的:观察益气养阴化瘀通络中药治疗早期糖尿病肾病的临床疗效及安全性。方法:选择糖尿病肾病患者60例,按随机数字表法分为两组,治疗组采用益气养阴化瘀通络中药进行治疗;对照组采用厄贝沙坦治疗。观察两组治疗后的疗效、临床症候积分和中医证候总积分变化及临床观察指标的变化。结果:治疗组总有效率为96.7%,对照组总有效率为76.7%,两组比较,差异有统计学意义(P<0.05);两组治疗后中医证候积分均显著降低,且治疗组与对照组比较,治疗后中医证候积分间差异有统计学意义(P<0.05);治疗后,两组临床观察指标较治疗前有显著改善,同对照组相比,治疗组临床观察指标均显著低于对照组(P<0.05);两组均未出现不良反应。结论:益气养阴化瘀通络中药对糖尿病肾病具有较好的临床疗效和安全性,可用于糖尿病肾病的治疗。
Objective: To observe the clinical efficacy and safety of Yiqi Yangyin Huayu Tongluo Chinese medicine in the treatment of early diabetic nephropathy. Methods: Sixty patients with diabetic nephropathy were divided into two groups according to the random number table. The treatment group was treated with Yiqi Yangyin Huayu Tongluo Chinese medicine. The control group was treated with irbesartan. After treatment, the curative effect, clinical symptom score, TCM syndrome total score changes and clinical observation indexes were observed. Results: The total effective rate was 96.7% in the treatment group and 76.7% in the control group. The difference between the two groups was statistically significant (P <0.05). The scores of TCM syndromes in the two groups were significantly decreased, and the treatment group Compared with the control group, the difference of TCM syndrome scores after treatment was statistically significant (P <0.05). After treatment, the clinical observation indexes in both groups were significantly improved compared with the control group. Compared with the control group, the clinical observation indicators in the treatment group Significantly lower than the control group (P <0.05); no adverse reactions were found in both groups. Conclusion: Yiqi Yangyin Huayu Tongluo Chinese medicine has a good clinical efficacy and safety for diabetic nephropathy, which can be used in the treatment of diabetic nephropathy.